Education
About Us
Working with TipRanks
Follow Us
PDS Biotechnology Corporation (PDSB)
NASDAQ:PDSB
PDSB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.13 - $4.92
Previous CloseN/A
Volume197.50K
Average Volume (3M)1.04M
Market Cap
$61.09M
Enterprise Value$115.52M
Total Cash (Recent Filing)$34.65M
Total Debt (Recent Filing)$30.00K
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Mar 27, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding44,589,516
10 Day Avg. Volume390,539
30 Day Avg. Volume1,035,916
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.02K
Enterprise Value/Ebitda-3.16
Forecast
1Y Price Target
$21.00Price Target Upside1432.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyIn HPV16-positive subgroup, the overall response rate increased to 62.5% by RECISTv1.1 and 75% by irRECIST, well above the 12-24% typically observed with standard-of-care ICIs.
Clinical TrialsFirst trial site initiated in VERSATILE-003, a global, multi-center, randomized, and open-label pivotal trial to evaluate the safety and efficacy of Versamune HPV in combination with pembrolizumab.
Regulatory ApprovalThe FDA has accepted its IND application to assess Versamune-MUC1 in combination with PDS01ADC to treat MUC1-positive unresectable, metastatic colorectal carcinoma.
Bears Say
Market EligibilityThe KN-689 study is not the population that would eventually be eligible for VERSATILE-003.
---
Ownership Overview
1.34% Insiders
4.46% Mutual Funds
0.74% Other Institutional Investors
89.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PDSB FAQ
What was PDS Biotechnology Corporation’s price range in the past 12 months?
PDS Biotechnology Corporation lowest stock price was $1.13 and its highest was $4.92 in the past 12 months.
What is PDS Biotechnology Corporation’s market cap?
PDS Biotechnology Corporation’s market cap is $61.09M.
When is PDS Biotechnology Corporation’s upcoming earnings report date?
PDS Biotechnology Corporation’s upcoming earnings report date is Mar 27, 2025 which is in 3 days.
How were PDS Biotechnology Corporation’s earnings last quarter?
PDS Biotechnology Corporation released its earnings results on Nov 14, 2024. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.297 by $0.007.
Is PDS Biotechnology Corporation overvalued?
According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued.
Does PDS Biotechnology Corporation pay dividends?
PDS Biotechnology Corporation does not currently pay dividends.
What is PDS Biotechnology Corporation’s EPS estimate?
PDS Biotechnology Corporation’s EPS estimate is -0.28.
How many shares outstanding does PDS Biotechnology Corporation have?
PDS Biotechnology Corporation has 44,589,516 shares outstanding.
What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?
PDS Biotechnology Corporation reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.297. Following the earnings report the stock price went down -18.478%.
Which hedge fund is a major shareholder of PDS Biotechnology Corporation?
Currently, no hedge funds are holding shares in PDSB
---
PDS Biotechnology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (1432.85% Upside)
$21.00 (1432.85% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 117.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $50.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.92%
12-Months-Change
Fundamentals
Return on Equity
-174.49%
Trailing 12-Months
Asset Growth
-8.28%
Trailing 12-Months
Company Description
PDS Biotechnology Corporation
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.
---
PDSB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong progress in clinical trials with significant improvements in clinical outcomes and promising data from IMMUNOCERV Phase II. Despite increased R&D expenses and some delays in other development areas, the overall sentiment is positive due to robust clinical results and strong interest in ongoing trials.Read More>---
PDSB Stock 12 Month Forecast
Average Price Target
$21.00
▲(1432.85% Upside)
Technical Analysis
Nektar Therapeutics
―
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Immunovant
―
Best Analysts Covering PDSB
1 Year
1 Year Success Rate
1/12 ratings generated profit
1 Year Average Return
-39.33%
reiterated a buy rating 12 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -39.33% per trade.
---